Are peptides legal? FDA status of every peptide people ask about

Whether a peptide is legal depends on two things: which molecule it is, and how it reached you. An FDA-approved drug prescribed by a licensed prescriber is legal. A pharmacy may compound a few substances, and as of November 2, 2026 an interim HHS policy tolerates six more under strict conditions. Anything else sold as a peptide is an unapproved new drug. This table is the reference page for our peptide basics and for every profile on the site. Each row gives the status, the basis for it and the date we last checked. Every row was checked on November 2, 2026 against FDA’s 503A category list (updated May 14, 2026), its 503B list (updated March 21, 2025), its safety page for bulk substances (April 22, 2026) and the HHS notice published October 30, 2026.

The five categories this site uses

Status table

What the October 2026 HHS policy does and does not do

The policy is a statement that HHS, through the Secretary’s office rather than FDA, does not intend to take enforcement action against a state-licensed pharmacy, federal facility or licensed physician compounding one of six peptides, when all ten conditions are met, until a final rule says whether each peptide goes on the 503A bulks list. The exact form and route matter, because the cover stops where the appendix stops.

All ten conditions have to be present:

1. The peptide is on the policy’s Appendix A list.
2. It has the identity and route limits in Appendix B.
3. The bulk substance comes from an FDA-registered facility with a valid certificate of analysis.
4. The original manufacturer is FDA-registered and compliant with current good manufacturing practice, with its location on the certificate.
5. The compounder reports serious adverse events and quality problems to FDA MedWatch and to the states involved.
6. The label reads: “This is a compounded drug product. Not for resale.”
7. The product contains a single active ingredient from the list, so blends are outside the policy.
8. For an oral product, the compounder keeps documentation that the formulation reaches adequate oral bioavailability in humans.
9. The only device packaged with it is an FDA 510(k)-cleared syringe.
10. It meets all other requirements of the Food, Drug, and Cosmetic Act, including a valid patient-specific prescription and no insanitary conditions.

Those conditions are narrow, and the limits matter as much as the list:

• It is not an approval. None of the six is FDA-approved and none is on the 503A bulks list. No rule has been proposed, and FDA has not reviewed any compounded product for safety, effectiveness or quality.
• It is a choice not to enforce. The notice says the policy “does not establish any rights for any person and is not binding on HHS or the public.” It calls the policy a draft in places and takes written comments until November 13, 2026.
• It can change. HHS may revisit it if a safety signal or product quality problem appears.
• It covers 503A compounding only. Outsourcing facilities under section 503B are not covered.
• States can be stricter. State boards of pharmacy license these pharmacies and keep their own rules, and states may not follow the federal approach.
• The evidence is unchanged. FDA’s drug center recommended against listing all six, and a decision about enforcement says nothing about whether a peptide works or is safe.

How 503A bulk substance categories work

Section 503A of the Food, Drug, and Cosmetic Act lets a licensed pharmacist in a state-licensed pharmacy, or a licensed physician, compound a drug for an individual patient without the approval, labeling and manufacturing rules that apply to drug companies. One condition is the source material. A bulk drug substance may be used only if it has a United States Pharmacopeia or National Formulary monograph, is a component of an FDA-approved drug, or appears on the 503A bulks list that FDA writes by regulation.

While it evaluates the substances nominated for that list, FDA sorts them into three categories under an interim policy:

• Category 1: nominated with enough information to evaluate; FDA does not intend to take enforcement action against compounding with these while the evaluation runs.
• Category 2: FDA has identified significant safety risks; compounding is not covered by the interim policy.
• Category 3: nominated without enough information to evaluate; not covered either.

FDA’s criteria for the list itself, set by a 2019 final rule, are physical and chemical characterization, safety, evidence of effectiveness or lack of it, and historical use in compounding, balanced substance by substance.

What is the PCAC?

The Pharmacy Compounding Advisory Committee is a panel of outside clinicians, pharmacists and scientists that FDA consults before deciding whether to add a substance to the bulks list. FDA presents its evaluation, the committee votes, and the vote is a recommendation. FDA’s July 2026 briefing document says the agency “does not intend to issue a final determination” until it has considered the committee’s input and finalized its reviews. It is free to disagree, and in July 2026 its staff already had.

A second meeting is expected before the end of February 2027. FDA’s May 2026 category list names GHK-Cu for it, and Holland & Knight reports LL-37, dihexa, melanotan II and PEG-MGF as the others. We found no announced date as of November 2, 2026.

What changes when a substance moves

Moving from category 2 to category 1 restores FDA’s interim enforcement policy, so compounding can resume while evaluation continues. Being removed from category 2 because a nominator withdrew, which is what happened to BPC-157 and most of the 2023 peptide batch in April 2026, is different. In the words of the HHS policy, “neither the placement nor the removal changed” the status of those substances under section 503A. The HHS policy then added a separate layer for six of them, and the rest stayed where they were.

Reaching the bulks list itself, through a proposed rule, public comment and a final rule, is the step that would bring a substance within section 503A. Even then it is not an approved drug: there is no label, no approved dose, and no manufacturer responsible for safety data.

Do state laws matter?

Yes, because federal law sets the floor. State boards of pharmacy license the pharmacies that compound under 503A and can impose stricter rules on what they compound, how prescriptions are written and whether out-of-state pharmacies may ship in. State medical boards separately decide whether prescribing an unapproved peptide falls within the standard of care. Rules vary enough that a prescriber or pharmacy should check their own state, but no state can make an unapproved peptide legal for human use when federal law says otherwise.

The practical test

Three questions settle almost every case. Is there a prescription from a licensed prescriber, written for you? Is it dispensed by a licensed pharmacy? Is the substance FDA-approved, one a pharmacy may lawfully compound, or within the exact form and route of the HHS policy? If any answer is no, the product is outside every route on this page.

A “research use only” label fails the test by definition. 21 CFR 312.160 permits such products to be shipped only for tests in laboratory animals or in vitro, with the words “Not for use in humans” on the label. FDA warning letters to peptide sellers in 2024 and 2026 have found that the disclaimer does not protect a seller whose marketing shows the product is meant for people, and it does not protect the person who injects it either. The HHS policy gives these products nothing. It says its aim is to “discourage the continued, widespread use of certain research-use-only peptides.”

For the most searched example, read the BPC-157 guide. Compounded versions of approved drugs have their own rules, covered in the compounded tirzepatide guide. If you are starting from scratch, begin with what peptides are, and read whether peptides are safe before weighing any of this as a green light.